Key terms
About CRSP
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRSP news
May 02
3:18am ET
Buy Rating on Crispr Therapeutics: Anticipated Clinical Catalysts and Undervalued Autoimmune Prospects
Apr 26
2:24am ET
Buy Rating on Crispr Therapeutics AG Backed by Exa-cel’s Precision and Favorable Safety Profile
Apr 24
4:55am ET
Crispr Therapeutics management to meet with Mizuho
Apr 23
8:08am ET
Crispr Therapeutics management to meet with Mizuho
Apr 19
7:31pm ET
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Apr 18
2:06pm ET
Crispr Therapeutics call volume above normal and directionally bullish
Apr 18
5:57am ET
Crispr Therapeutics price target raised to $89 from $88 at Citi
Apr 03
1:46am ET
Buy Rating Affirmed for Crispr Therapeutics AG on Promising Gene Editing Developments and Expanding Treatment Pipeline
Mar 31
10:29pm ET
Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?
Mar 30
3:48pm ET
Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?
Mar 29
4:30am ET
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)
Mar 14
12:50pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Mar 14
11:41am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Mar 13
8:40am ET
Crispr Therapeutics proposes to elect Christian Rommel to board of directors
Mar 06
7:02am ET
Crispr Therapeutics price target raised to $99 from $82 at Mizuho
Feb 27
7:47am ET
Crispr Therapeutics AG (CRSP) Receives a Buy from Truist Financial
Feb 25
11:40pm ET
Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)
Feb 22
10:25am ET
Crispr Therapeutics call volume above normal and directionally bullish
Feb 22
9:33am ET
Crispr Therapeutics price target raised to $66 from $57 at RBC Capital
Feb 22
7:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Alcon (ALC) and Outset Medical (OM)
Feb 22
7:24am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Community Health (CYH), Crispr Therapeutics AG (CRSP) and Ansell (OtherANSLF)
Feb 22
7:11am ET
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)
Feb 22
7:04am ET
Crispr Therapeutics price target raised to $70 from $55 at Wells Fargo
Feb 22
5:31am ET
Crispr Therapeutics price target raised to $80 from $61 at Barclays
Feb 22
5:12am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Icon (ICLR) and Crispr Therapeutics AG (CRSP)
Feb 21
6:35pm ET
Buy Rating for Crispr Therapeutics AG: Strong Financials and Promising Gene-Editing Pipeline
Feb 21
6:26pm ET
Crispr Therapeutics price target raised to $112 from $110 at Chardan
Feb 21
12:45pm ET
Strong Buy Rating for Crispr Therapeutics AG on Robust Financials and Positive Casgevy Outlook
Feb 21
12:00pm ET
Analysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH) and Crispr Therapeutics AG (CRSP)
Feb 21
11:25am ET
Buy Rating Affirmed for Crispr Therapeutics AG on Robust Pipeline and Expanding Global Reach
Feb 21
10:30am ET
Analysts Conflicted on These Healthcare Names: Globus Medical (GMED) and Crispr Therapeutics AG (CRSP)
No recent press releases are available for CRSP
CRSP Financials
Key terms
Ad Feedback
CRSP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRSP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range